STAT

Biotech VC Bob Nelsen called it right on the coronavirus. Now he has thoughts on therapeutics — and masks

One of biotech’s most successful venture capitalists was once cast as an alarmist on the coronavirus. He was right.
Source: Dr. Fred Murphy, Sylvia Whitfield/CDC

Bob Nelsen was right.

The co-founder and managing partner of Arch Venture Partners is one of biotech’s most successful venture capitalists. He’s also deeply wary of unchecked viruses, a fear he shares regularly with friends, family, and his Twitter followers. “Flu. Get shot. Get antivirals. Don’t die,” Nelsen tweeted right before Christmas.

Most people don’t worry about viruses the way Nelsen does, so when his tweets started to take on a much darker tone in January, I paid little attention. It was just Bob being Bob.

“Very scary,” he warned on Jan. 20, linking to a report of human-to-human transmission of a novel coronavirus in China. A day later, he likened the emerging outbreak to the video game Plague and said he was shorting airline stocks.

And then on Jan. 31, there was this

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks